Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACET | Adicet Bio, Inc.

IndexRUT P/E- EPS (ttm)-2.70 Insider Own0.70% Shs Outstand42.96M Perf Week-3.61%
Market Cap72.14M Forward P/E- EPS next Y-2.75 Insider Trans- Shs Float41.80M Perf Month-15.34%
Income-115.20M PEG- EPS next Q-0.74 Inst Own96.07% Short Float / Ratio6.45% / 2.87 Perf Quarter-65.37%
Sales0.00M P/S- EPS this Y15.20% Inst Trans9.40% Short Interest2.70M Perf Half Y-75.65%
Book/sh5.57 P/B0.29 EPS next Y6.80% ROA-36.30% Target Price20.33 Perf Year-88.64%
Cash/sh4.56 P/C0.35 EPS next 5Y29.10% ROE-41.30% 52W Range1.60 - 21.87 Perf YTD-82.10%
Dividend- P/FCF- EPS past 5Y27.40% ROI-24.80% 52W High-92.68% Beta1.98
Dividend %- Quick Ratio11.10 Sales past 5Y- Gross Margin- 52W Low0.00% ATR0.14
Employees132 Current Ratio11.10 Sales Q/Q- Oper. Margin- RSI (14)35.32 Volatility7.75% 6.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-34.10% Profit Margin- Rel Volume0.21 Prev Close1.70
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume939.25K Price1.60
Recom2.00 SMA20-8.91% SMA50-28.43% SMA200-73.67% Volume195,825 Change-5.88%
Date Action Analyst Rating Change Price Target Change
Jun-27-23Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-23Downgrade Guggenheim Buy → Neutral
Jun-01-23Downgrade JP Morgan Overweight → Neutral $20 → $6
Sep-21-22Initiated JP Morgan Overweight $23
Mar-31-22Initiated SMBC Nikko Outperform $28
Mar-08-22Initiated Truist Buy $30
Mar-04-22Initiated Jefferies Buy $27
May-18-21Initiated BTIG Research Buy $34
Apr-23-21Initiated H.C. Wainwright Buy $27
Apr-14-21Initiated Canaccord Genuity Buy $28
Oct-16-20Initiated Wedbush Outperform $25
Aug-31-23 04:35PM
Aug-12-23 08:16AM
Aug-09-23 04:15PM
Aug-02-23 04:00PM
Jul-31-23 04:50PM
08:30AM Loading…
Jul-11-23 08:30AM
Jun-30-23 04:51PM
Jun-26-23 04:00PM
Jun-01-23 07:00AM
May-31-23 04:53PM
May-18-23 06:00AM
May-09-23 04:30PM
Apr-28-23 05:13PM
Apr-26-23 08:01PM
06:58AM Loading…
Apr-17-23 06:58AM
Apr-13-23 07:00AM
Apr-04-23 02:47PM
Mar-31-23 04:31PM
Mar-15-23 04:01PM
Mar-09-23 07:00AM
Mar-05-23 07:09AM
Feb-28-23 05:31PM
Feb-01-23 07:00AM
Jan-31-23 08:40PM
Dec-30-22 04:43PM
Dec-20-22 08:23AM
Dec-10-22 10:00AM
Dec-02-22 07:00AM
08:08PM Loading…
Nov-30-22 08:08PM
Nov-29-22 07:00AM
Nov-11-22 05:24AM
Nov-08-22 04:10PM
Nov-07-22 08:00AM
Nov-03-22 09:00AM
Nov-01-22 07:00AM
Oct-31-22 06:58PM
Oct-23-22 08:39AM
Oct-05-22 08:00AM
Sep-30-22 06:59PM
Sep-26-22 06:26AM
Sep-07-22 04:10PM
Aug-31-22 05:30PM
Aug-16-22 06:16AM
Aug-10-22 07:00AM
Aug-01-22 04:10PM
Jul-29-22 06:05PM
Jul-01-22 04:10PM
Jun-21-22 04:10PM
Jun-06-22 07:00AM
Jun-03-22 04:10PM
May-26-22 05:00PM
May-18-22 04:00PM
May-15-22 08:21AM
May-12-22 04:10PM
May-05-22 07:00AM
May-04-22 04:10PM
Apr-27-22 10:00AM
Apr-19-22 07:00AM
Apr-07-22 04:10PM
Apr-01-22 04:10PM
Mar-22-22 12:47PM
Mar-15-22 04:00PM
Mar-04-22 04:00PM
Feb-02-22 07:00AM
Dec-10-21 04:01PM
Dec-09-21 05:49PM
Dec-08-21 01:13AM
Dec-07-21 04:16PM
Dec-06-21 07:00AM
Nov-29-21 07:00AM
Nov-20-21 06:00AM
Nov-18-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 04:01PM
Nov-08-21 07:00AM
Nov-04-21 09:00AM
Oct-26-21 03:00AM
Oct-12-21 04:10PM
Oct-04-21 07:00AM
Sep-13-21 08:00AM
Sep-02-21 04:53PM
Aug-12-21 04:01PM
Aug-02-21 07:00AM
Jul-30-21 10:35AM
Jul-15-21 07:00AM
Jun-28-21 07:00AM
May-18-21 04:10PM
May-17-21 07:01AM
Apr-29-21 07:00AM
Apr-15-21 07:00AM
Apr-13-21 07:00AM
Mar-11-21 04:10PM
Mar-10-21 07:00AM
Mar-04-21 04:01PM
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUBIN STEVEDirectorJun 30Buy2.405,00012,00010,900Jun 30 04:08 PM
GORDON CARL LDirectorJun 27Buy2.09875,0001,828,7505,685,259Jun 29 04:51 PM
ORBIMED ADVISORS LLCDirectorJun 27Buy2.09875,0001,828,7505,685,259Jun 29 04:46 PM
Healey DonChief Technology OfficerFeb 15Sale7.574,53334,32766,568Feb 17 08:22 PM
Healey DonChief Technology OfficerFeb 10Sale7.9810,46783,47671,101Feb 14 04:50 PM
Schor ChenPresident & CEONov 10Sale20.0630,000601,92053,424Nov 15 04:31 PM
Schor ChenPresident & CEONov 10Sale21.039,955209,32291,469Nov 15 04:31 PM
Aftab BlakeChief Scientific OfficerNov 10Sale21.006,967146,30728,209Nov 15 04:32 PM
Schor ChenPresident & CEONov 07Sale19.0530,000571,48883,424Nov 09 04:05 PM
Schor ChenPresident & CEONov 03Sale18.0424,813447,718113,424Nov 04 05:23 PM
Schor ChenPresident & CEONov 02Sale18.005009,000138,237Nov 04 05:23 PM
Aftab BlakeChief Scientific OfficerOct 19Sale16.278,067131,25035,176Oct 21 04:10 PM
Aftab BlakeChief Scientific OfficerOct 12Option Exercise7.383,38825,00352,822Oct 14 04:08 PM
Aftab BlakeChief Scientific OfficerOct 12Sale15.401,64625,34851,176Oct 14 04:08 PM